Alkermes plc. (ALKS) Current Ratio
- Current ratio · latest quarter: Value 2.30×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.30× | Current assets / current liabilities. $1.52B ÷ $662.09M ≈ 2.30× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 1.52B USD | Assets, Current |
| Current obligations | 662.09M USD | Liabilities, Current |
| Cash and equivalents | 511.53M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 145.05M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | 298.96M USD | Inventory, Net |
| Payables | 142.86M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 26.50M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.52B | $662.09M | $511.53M | $145.05M | (m) | $298.96M | $142.86M | $26.50M | 2.30× |
| 2026-03-31 | $1.36B | $599.50M | $351.55M | $160.31M | (m) | $336.70M | $102.36M | $26.50M | 2.27× |
| 2025-12-31 | $1.93B | $543.44M | $388.57M | $199.65M | (m) | $196.63M | $107.95M | $0.00 | 3.55× |
| 2025-09-30 | $1.74B | $474.36M | $616.45M | $494.67M | (m) | $191.00M | $68.00M | (m) | 3.67× |
| 2025-06-30 | $1.64B | $505.96M | $521.20M | $494.54M | (m) | $191.92M | $99.21M | (m) | 3.23× |
| 2025-03-31 | $1.48B | $443.73M | $399.81M | $484.21M | (m) | $183.44M | $59.84M | (m) | 3.33× |
| 2024-12-31 | $1.42B | $465.20M | $291.15M | $460.52M | (m) | $182.89M | $45.63M | (m) | 3.04× |
| 2024-09-30 | $1.56B | $453.70M | $396.29M | $512.57M | (m) | $191.09M | $37.04M | $3.00M | 3.45× |
| 2024-06-30 | $1.54B | $515.55M | $535.15M | $340.97M | (m) | $194.73M | $104.75M | $3.00M | 2.99× |
| 2024-03-31 | $1.47B | $458.98M | $420.75M | $324.30M | (m) | $198.37M | $77.05M | $3.00M | 3.20× |
| 2023-12-31 | $1.49B | $520.22M | $457.47M | $316.02M | (m) | $186.41M | $65.65M | $3.00M | 2.86× |
| 2023-09-30 | $1.46B | $503.11M | $647.71M | $241.44M | (m) | $192.19M | $87.04M | $3.00M | 2.91× |
| 2023-06-30 | $1.40B | $487.19M | $665.79M | $163.25M | (m) | $189.37M | $84.62M | $3.00M | 2.87× |
| 2023-03-31 | $1.11B | $492.91M | $321.40M | $279.06M | (m) | $184.98M | $37.15M | $3.00M | 2.25× |
| 2022-12-31 | $1.13B | $497.74M | $292.47M | $315.99M | (m) | $181.42M | $32.84M | $3.00M | 2.27× |
| 2022-09-30 | $1.05B | $469.56M | $263.96M | $316.23M | (m) | $166.30M | $33.20M | $3.00M | 2.24× |
| 2022-06-30 | $1.05B | $438.52M | $254.65M | $326.32M | (m) | $155.61M | $40.05M | $3.00M | 2.39× |
| 2022-03-31 | $1.01B | $462.36M | $282.56M | $246.31M | (m) | $154.79M | $27.70M | $3.00M | 2.19× |
| 2021-12-31 | $1.06B | $471.29M | $337.54M | $198.77M | (m) | $150.34M | $55.72M | $3.00M | 2.25× |
| 2021-09-30 | $1.05B | $452.98M | $310.44M | $249.86M | (m) | $138.70M | $36.88M | $3.00M | 2.32× |
| 2021-06-30 | $1.04B | $383.44M | $258.34M | $280.00M | (m) | $136.08M | $32.80M | $3.00M | 2.71× |
| 2021-03-31 | $1.01B | $365.84M | $205.03M | $335.97M | (m) | $134.18M | $36.10M | $3.00M | 2.75× |
| 2020-12-31 | $1.11B | $438.26M | $272.96M | $362.07M | (m) | $125.74M | $46.03M | $2.84M | 2.53× |
| 2020-09-30 | $1.02B | $378.15M | $240.87M | $328.52M | (m) | $122.82M | $82.83M | $2.84M | 2.71× |
| 2020-06-30 | $947.36M | $321.41M | $189.00M | $343.56M | (m) | $116.46M | $50.94M | $2.84M | 2.95× |
| 2020-03-31 | $912.58M | $339.85M | $176.07M | $319.93M | (m) | $109.31M | $43.18M | $2.84M | 2.69× |
| 2019-12-31 | $961.97M | $391.11M | $203.77M | $331.21M | (m) | $101.80M | $54.26M | $2.84M | 2.46× |
| 2019-09-30 | $997.92M | $370.39M | $261.43M | $325.76M | (m) | $100.99M | $81.42M | $2.84M | 2.69× |
| 2019-06-30 | $994.60M | $334.15M | $195.95M | $374.34M | (m) | $94.78M | $42.88M | $2.84M | 2.98× |
| 2019-03-31 | $962.74M | $327.69M | $225.23M | $356.89M | (m) | $92.86M | $48.96M | $2.84M | 2.94× |
| 2018-12-31 | $983.25M | $339.77M | $266.76M | $272.53M | (m) | $90.20M | $39.77M | $2.84M | 2.89× |
| 2018-09-30 | $869.76M | $304.79M | $216.04M | $251.05M | (m) | $88.02M | $44.11M | $2.84M | 2.85× |
| 2018-06-30 | $840.12M | $287.47M | $155.85M | $277.66M | (m) | $87.17M | $57.88M | $2.84M | 2.92× |
| 2018-03-31 | $776.14M | $274.53M | $186.50M | $218.06M | (m) | $84.88M | $65.45M | $2.84M | 2.83× |
| 2017-12-31 | $808.84M | $291.12M | $191.30M | $242.21M | (m) | $93.28M | $55.53M | $3.00M | 2.78× |
| 2017-09-30 | $781.55M | $256.01M | $165.12M | $284.98M | (m) | $85.03M | $52.72M | $3.00M | 3.05× |
| 2017-06-30 | $795.63M | $224.64M | $158.11M | $317.00M | (m) | $77.35M | $54.68M | $3.00M | 3.54× |
| 2017-03-31 | $758.85M | $210.74M | $181.31M | $295.11M | (m) | $63.67M | $56.71M | $3.00M | 3.60× |
| 2016-12-31 | $790.68M | $211.99M | $186.38M | $310.86M | (m) | $63.00M | $46.27M | $3.00M | 3.73× |
| 2016-09-30 | $807.26M | $190.24M | $202.24M | $347.22M | (m) | $54.16M | $43.82M | $3.00M | 4.24× |
| 2016-06-30 | $929.25M | $236.26M | $196.44M | $459.54M | (m) | $49.90M | $36.29M | $63.91M | 3.93× |
| 2016-03-31 | $838.56M | $224.13M | $199.98M | $425.41M | (m) | $44.82M | $33.01M | $64.83M | 3.74× |
| 2015-12-31 | $754.96M | $236.21M | $181.11M | $353.67M | (m) | $38.41M | $37.40M | $65.74M | 3.20× |
| 2015-09-30 | $1.00B | $200.40M | $222.34M | $549.42M | (m) | $36.78M | $27.76M | $66.71M | 4.99× |
| 2015-06-30 | $1.02B | $134.22M | $196.89M | $579.88M | (m) | $38.80M | $26.95M | $6.75M | 7.58× |
| 2015-03-31 | $1.00B | $114.22M | $209.31M | $538.15M | (m) | $49.14M | $25.29M | $6.75M | 8.79× |
| 2014-12-31 | $876.79M | $130.58M | $224.06M | $407.10M | (m) | $51.36M | $32.34M | $6.75M | 6.71× |
| 2014-09-30 | $812.91M | $110.14M | $136.18M | $436.39M | (m) | $50.47M | $27.23M | $6.75M | 7.38× |
| 2014-06-30 | $886.92M | $102.16M | $188.32M | $450.17M | (m) | $57.07M | $21.26M | $6.75M | 8.68× |
| 2014-03-31 | $776.77M | $92.76M | $156.32M | $395.95M | (m) | $55.40M | $24.30M | $6.75M | 8.37× |
| 2013-12-31 | $570.14M | $100.90M | $167.56M | $194.67M | (m) | $46.22M | $19.49M | $6.75M | 5.65× |
| 2013-09-30 | $523.58M | $73.72M | $173.50M | $165.92M | (m) | $40.71M | $12.12M | $6.75M | 7.10× |
| 2013-06-30 | $422.08M | $72.60M | $116.40M | $112.14M | (m) | $39.13M | $14.21M | $6.75M | 5.81× |
| 2013-03-31 | $408.59M | $85.93M | $96.96M | $124.39M | (m) | $43.48M | $18.28M | $6.75M | 4.75× |
| 2012-12-31 | $387.52M | $77.28M | $135.89M | $73.41M | (m) | $45.69M | $14.40M | $6.75M | 5.01× |
| 2012-09-30 | $354.92M | $68.74M | $132.42M | $67.03M | (m) | $40.89M | $15.59M | $6.75M | 5.16× |
| 2012-06-30 | $352.41M | $71.24M | $85.60M | $78.77M | (m) | $41.44M | $12.77M | $3.10M | 4.95× |
| 2012-03-31 | $339.15M | $89.16M | $83.60M | $106.85M | (m) | $39.76M | $18.40M | $3.10M | 3.80× |
| 2011-12-31 | $375.14M | $97.20M | $85.33M | $128.10M | (m) | $46.11M | (m) | $3.10M | 3.86× |
| 2011-09-30 | $355.71M | $90.32M | $89.24M | $126.33M | (m) | $47.12M | (m) | $2.33M | 3.94× |
| 2011-03-31 | $252.96M | $48.06M | $38.39M | $162.93M | (m) | $20.43M | $9.27M | (m) | 5.26× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |